Chlamydia Screening for Women (NQF 0033)

EMeasure Name Chlamydia Screening for Women EMeasure Id 916A51C2-4331-45F5-B415-66F15374B869
Version number 1 Set Id E03E8BD8-0DA7-49AC-835F-EAC4B8EAF616
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward National Committee for Quality Assurance
Endorsed by National Quality Forum
Description The percentage of women 15-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.
Copyright
© National Committee for Quality Assurance. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
Population 1: age 14-23 starts before the start of measurement end date
Population 2: age 14-19 starts before the start of measurement end date 
Population 3: age 20-23 starts before the start of measurement end date
Note: The upper age limit of 23 before the measurement year will address all patients reaching the age of 24 during the measurement year. Similarly, the lower age limit of 14 before the measurement year will address all patients reaching the age of 15 during the measurement year.
Risk Adjustment
None
Data Aggregation
Rationale
This measure assesses appropriate screening for chlamydia among women in a specific age demographic. Chlamydia is one of the most frequently occurring sexually-transmitted diseases in the United States, resulting in over 2.8 million new cases each year. Women 14–30 are particularly susceptible and account for over 80% of new cases, according to the U.S. National Health and Nutrition Examination Survey. Additionally, heath care costs attributable to chlamydia and its complications exceed $3.5 billion per year in the U.S.. Early detection and treatment have proven to be effective in preventing and managing chlamydia. Several studies have shown that screening reduces overall disease prevalence by 4.2% and is strongly correlated with a reduced incidence of pelvic inflammatory disease (PID). This measure facilitates efforts toward early screening and treatment to improve health outcomes for infected women and prevent the spread of disease.
Clinical Recommendation Statement
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians routinely screen all sexually active women aged 25 years and younger, and other asymptomatic women at increased risk for infection, for chlamydial infection.  Rating: A recommendation (http://www.ahrq.gov/clinic/uspstf/uspschlm.htm). 

The American Academy of Family Physicians (AAFP, 2005) strongly recommends screening all sexually active females age 25 years or younger and other women at increased risk for chlamydia.

American College of Preventive Medicine:  Sexually active women with risk factors should be screened annually by any well-validated, laboratory-based amplification or antigen method, using cervical or urine specimens. Risk factors include age <=25 years, a new male sex partner or two or more partners during the preceding year, inconsistent use of barrier contraception, history of a prior sexually transmitted disease (STD), African-American race, and cervical ectopy. All partners of women with positive tests should be tested for Chlamydia trachomatis. Women with mucopurulent discharge, suggestive of cervicitis, should be tested immediately.

The American College of Obstetricians and Gynecologists recommends routine screening for chlamydial infection for all sexually active adolescents and other asymptomatic women at high risk for infection.
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
American College of Obstetricians and Gynecologists, ACOG Committee on Primary Care. Committee Opinion No. 229. Washington DC: ACOG, 1999
Reference
Hollblad-Fadiman K, Goldman SM.  American College of Preventive Medicine Practice Policy Statement: Screening for Chlamydia trachomatis.  American Journal of Preventive Medicine 2003; 24(3)
Reference
U.S. Preventive Services Task Force. Screening for chlamydial infection—including ocular prophylaxis in newborns. In: Guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams & Wilkins; 1996.
Definition
Guidance

Table of Contents


Population criteria

      ------ Population Criteria 1 ------

      ------ Population Criteria 2 ------

      ------ Population Criteria 3 ------

Data criteria (QDS Data Elements)

Summary Calculation

Calculation is generic to all measures:



Measure set CLINICAL QUALITY MEASURE SET 2011-2012